AMRX vs LENZ
AMRX: Amneal Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of a diverse portfolio of generic and specialty medicines. LENZ: LENZ Therapeutics is a commercial-stage ophthalmology company marketing VIZZ, a first-of-its-kind, once-daily aceclidine-based eye drop for treating presbyopia.
Side-by-side fundamentals
| Metric | AMRX | LENZ | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $19.84 | $3.19 | |
| Market cap | $6.3B | $100M | |
| P/E as of 2026-10-20 | 41.33 | n/a | |
| Net margin FY2025, SEC XBRL | +2.4% | -430.3% | AMRX higher |
| Gross margin FY2025, SEC XBRL | +36.9% | n/a | |
| Operating margin FY2025, SEC XBRL | +13.1% | -477.5% | AMRX higher |
| ROE FY2025, SEC XBRL | n/a | -28.9% | |
| ROA FY2025, SEC XBRL | +2.0% | -26.8% | AMRX higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 77.83 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +8.1% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +10.9% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.82 | 1.66 | |
| 1-year return as of 2026-10-20 close | +93.8% | -91.2% | AMRX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.